DELRAY BEACH, Fla., Jan. 23, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics Inc. subsidiary ("Thermomedics"), which markets the FDA-cleared Caregiver® non-contact thermometer, has entered into a new distribution agreement with MedPro Associates. MedPro, a national contracted sales firm, will market Caregiver primarily to the alternate site and long-term care markets, along with targeted acute care facilities.
Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Caregiver requires minimal training and is proven as accurate as other methods of clinical thermometry, which include predictive oral/rectal/axillary electronic, infrared tympanic, temporal artery contact scanner, etc. Other temperature monitoring devices may require protective probe covers, intensive technique concentration, which make them prone to mistaken placement or dwell time, and may require replacement metal probes, cords, or other parts.
Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk
of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.
"MedPro has a long-standing reputation of delivering results due to its strong relationships throughout the healthcare industry over the last decade," stated William J. Caragol, Chairman and CEO of PositiveID. "We believe that adding MedPro to our distributor portfolio will enable us to increase sales and build a strong pipeline of opportunities for 2017."
MedPro is a national contracted sales firm specializing in the healthcare industry. MedPro represents leading manufacturers who sell their products into clinics, surgery centers, dialysis centers, school health, longterm care, physician offices, homecare, and the federal government, along with acute care facilities. A formula that combines experience, knowledge, proven results and most importantly, strong relationships, make MedPro an industry leader in contract sales for medical manufacturers.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics
systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the likelihood that MedPro will market Caregiver primarily to the alternate site and long-term care markets, along with targeted acute care facilities; the likelihood that since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of
cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; the likelihood that adding MedPro to the Company's distributor portfolio will enable it to increase sales and build a strong pipeline of opportunities for 2017; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and
PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the specialty vehicle market; the Company's ability to turn qualified pipeline opportunities into purchase orders; the possibility that a purchase order could be canceled; the Company's ability to keep existing customers and attract new customers; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on November 18, 2016, August 12, 2016, and May 16, 2016, under the caption "Risk Factors." The Company
undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Source: PositiveID Corporation
News Provided by Acquire Media